We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
+5.18%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$9.58B
AUM Growth
+$79.4M
Cap. Flow
-$279M
Cap. Flow %
-2.91%
Top 10 Hldgs %
37.69%
Holding
157
New
16
Increased
39
Reduced
32
Closed
21

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$158M
2
MOH icon
Molina Healthcare
MOH
+$98.2M
3
MRK icon
Merck
MRK
+$95.1M
4
ZBH icon
Zimmer Biomet
ZBH
+$88.5M
5
MDVN
MEDIVATION, INC.
MDVN
+$85.1M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$182M
2
CELG
Celgene Corp
CELG
+$142M
3
HCA icon
HCA Healthcare
HCA
+$129M
4
AGN.PRA
Allergan plc
AGN.PRA
+$87M
5
TSRO
TESARO, Inc.
TSRO
+$84.2M

Sector Composition

Rank Sector Weight
1 Healthcare 89.03%
2 Financials 0.34%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
101
Syndax Pharmaceuticals
SNDX
$1.69B
$7.46M 0.08%
757,365
– –
ALKS icon
102
Alkermes
ALKS
$8.2B
$7.43M 0.08%
+172,000
New +$7.1M
WMGI
103
CALL
DELISTED
Wright Medical Group Inc
WMGI
$6.95M 0.07%
+400,000
New +$7.34M
SYRE icon
104
Spyre Therapeutics
SYRE
$8.32B
$6.61M 0.07%
+54,409
New +$10.4M
RDHL
105
Redhill Biopharma
RDHL
$4.26M
$6.14M 0.06%
565
– –
ADAP
106
DELISTED
Adaptimmune Therapeutics
ADAP
$5.9M 0.06%
724,184
+285,400
+65% +$2.69M
BCR
107
DELISTED
CR Bard Inc.
BCR
$5.41M 0.06%
+23,000
New +$5M
INFI
108
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.32M 0.05%
3,250,300
-473,228
-13% -$2.21M
MGNX icon
109
MacroGenics
MGNX
$235M
$4.03M 0.04%
149,400
-167,600
-53% -$3.78M
BHC icon
110
Bausch Health
BHC
$1.69B
$3.92M 0.04%
194,900
– –
ADXS
111
DELISTED
Advaxis Inc
ADXS
$3.6M 0.04%
29,693
-12,747
-30% -$1.63M
NVTA
112
DELISTED
Invitae Corporation
NVTA
$3.38M 0.04%
456,666
– –
NERV icon
113
Minerva Neurosciences
NERV
$191M
$3.28M 0.03%
+40,188
New +$2.56M
MCRB icon
114
Seres Therapeutics
MCRB
$46M
$2.5M 0.03%
4,300
-4,032
-48% -$2.37M
INSM icon
115
CALL
Insmed
INSM
$22.7B
$1.97M 0.02%
+200,000
New +$2.33M
ROKA
116
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$1.84M 0.02%
322,043
– –
QURE icon
117
uniQure
QURE
$2.72B
$1.44M 0.02%
195,400
+10,600
+6% +$127K
MRNS
118
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.1M 0.01%
216,900
-24,350
-10% -$448K
XYLO
119
DELISTED
Xylo Technologies
XYLO
$1.09M 0.01%
375
– –
AMED
120
DELISTED
Amedisys
AMED
$1.01M 0.01%
+20,000
New +$1.01M
CGNT
121
DELISTED
Cogentix Medical, Inc.
CGNT
$953K 0.01%
990,745
– –
XTNT icon
122
Xtant Medical Holdings
XTNT
$59.1M
$908K 0.01%
39,620
– –
BLRX
123
BioLineRX
BLRX
$12.3M
$831K 0.01%
1,731
– –
AMRN
124
Amarin Corp
AMRN
$298M
$756K 0.01%
17,500
– –
QLTI
125
DELISTED
QLT Inc
QLTI
$710K 0.01%
500,000
– –
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q2 2016 Portfolio in Review

As of Q2 2016, OrbiMed held 157 positions worth $9.58B, up 0.84% from $9.5B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

OrbiMed's Q2 2016 filing shows 16 new, 39 increased, 32 reduced and 21 closed positions. Its largest new stake was Molina Healthcare: 1,838,000 shares worth $91.7M. The largest sale was Bristol-Myers Squibb, an estimated $182M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Financials and Technology.

  • OrbiMed's largest Q2 2016 buy was Molina Healthcare: 1,838,000 shares worth $91.7M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q2 2016, an estimated $158M increase.
  • OrbiMed's biggest Q2 2016 reduction was Bristol-Myers Squibb, cutting an estimated $182M.
  • OrbiMed fully exited Allergan plc in Q2 2016, selling an estimated $87M.
  • OrbiMed's ten largest holdings make up 38% of its $9.58B portfolio in Q2 2016.
  • OrbiMed opened 16 new positions and closed 21 in Q2 2016.
  • OrbiMed's portfolio value rose 0.84% quarter-over-quarter to $9.58B.

Based on OrbiMed's 13F filing for Q2 2016, filed 15 Aug 2016.